PROK PROKIDNEY CORP.

Nasdaq Biological Products, (No Diagnostic Substances) E9 CIK: 0001850270
AI RATING
STRONG_SELL
85% Confidence

Investment Thesis

ProKidney Corp exhibits severe financial distress with negative stockholders' equity (-$1.0B), massive operating losses (-$165M on $893K revenue), and unsustainable cash burn (-$135.3M FCF). With current cash reserves (~$108.5M) and burn rate exceeding $135M annually, the company faces insolvency within 12 months unless it achieves significant revenue acceleration or obtains additional financing.

Strengths

  • + Strong revenue growth rate (+1075% YoY, though from minimal base)
  • + Net loss improving substantially YoY (+54.5% improvement)
  • + Adequate short-term liquidity with $108.5M cash and 9.13x current ratio

Risks

  • ! Negative stockholders' equity indicating technical insolvency on book value basis
  • ! Catastrophic burn rate: -$135.3M free cash flow annually with <1 year cash runway
  • ! Operating margin of -18477.8% demonstrates business model is severely unprofitable at current scale
  • ! Minimal revenue generation relative to operating expenses indicates early/failed commercialization

Key Metrics to Watch

Financial Metrics

Revenue
893.0K
Net Income
-69.0M
EPS (Diluted)
$-0.23
Free Cash Flow
-135.3M
Total Assets
335.6M
Cash
108.5M

Profitability Ratios

Gross Margin N/A
Operating Margin -18,477.8%
Net Margin -7,725.2%
ROE N/A
ROA -20.6%
FCF Margin -15,152.6%

Balance Sheet & Liquidity

Current Ratio
9.13x
Quick Ratio
9.13x
Debt/Equity
N/A
Debt/Assets
10.4%
Interest Coverage
-41,251.75x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-04-14T15:21:22.530354 | Data as of: 2025-12-31 | Powered by Claude AI